Identification of Leydig cell-specific mRNA transcripts in the adult rat testis

P J O'Shaughnessy, A Monteiro, P A Fowler¹ and I D Morris²

Division of Cell Sciences, Institute of Biodiversity, Animal Health and Comparative Medicine, University of Glasgow, Bearsden Road, Glasgow G61 1QH, UK, ¹Division of Applied Medicine, Institute of Medical Sciences, University of Aberdeen, Aberdeen AB25 2ZD, UK and ²Hull York Medical School, The University of York, John Hughlings Jackson Building, York YO10 5DD, UK

Correspondence should be addressed to P J O'Shaughnessy; Email: peter.oshaughnessy@glasgow.ac.uk

Abstract

The adult population of Leydig cells acts to secrete testosterone which is essential for reproductive health and fertility in the adult male. However, other physiological functions of these cells are uncertain, and to address this issue a cell ablation model has been used to identify Leydig cell-specific mRNA transcripts. Ethane dimethane sulphonate (EDS) was synthesised by a novel process and was used to ablate Leydig cells in adult male rats previously treated with butane dimethane sulphonate (busulphan) to delete the germ cell population. Levels of mRNA transcripts were measured in the testis using microarrays 1, 3, 5, 8 and 12 days after EDS injection. During this period, there was a significant change in the levels of 2200 different transcripts with a marked decline in the levels of canonical Leydig cell transcripts, such as *Cyp11a1*, *Cyp17a1* and *InsI3*. A total of 95 transcripts showed a similar decline in expression after EDS treatment, suggesting that they have a Leydig cell-specific origin. Analysis of selected transcripts confirmed that they were expressed specifically in Leydig cells and showed that most had a late onset of expression during adult Leydig cell development. Apart from transcripts encoding components of the steroidogenic apparatus, the most common predicted function of translated proteins was endogenous and xenotoxicant metabolism. In addition, a number of transcripts encode acute-phase proteins involved in reduction of oxidative stress. Results show that, in addition to androgen secretion, Leydig cells may have a critical role to play in protecting the testis from damage caused by toxicants or stress.

Reproduction (2014) **147** 671–682

Introduction

During testicular development, two populations of Leydig cells arise sequentially. The foetal population differentiates soon after the start of testis development and is responsible for foetal androgen production and induction of masculinisation. In rodents, the foetal population is replaced shortly after birth by a second 'adult' population that maintains testicular androgen production throughout the adult lifespan of the animal. These two populations appear to represent distinct cell lineages and show clear differences in their regulation and pattern of development. The adult population starts to develop around postnatal day 12 in the rat (Ariyaratne *et al.* 2000) and days 7–10 in the mouse (Baker *et al.* 1999, Nef *et al.* 2000). Thereafter, cell numbers increase rapidly in the immediate pre-pubertal period, so that by day 30 both Leydig cell numbers and androgen production are close to adult levels (Vergouwens *et al.* 1993, Baker & O'Shaughnessy 2001a, O'Shaughnessy *et al.* 2002, Baker *et al.* 2003a). The primary function of the adult Leydig cell population is to secrete androgens that are essential for both somatic cell function and germ cell development in the testis and for the development and

maintenance of the male phenotype and sexual behaviour. It is less clear, however, whether the adult Leydig cells have other functions in either testis biology or systemic metabolism. To understand the role of the Leydig cell, a comprehensive list of transcripts strongly and uniquely expressed in these cells is a prerequisite. Previous studies have generated lists of transcripts expressed in Leydig cells by microarray analysis of isolated cells (Stanley *et al.* 2011). While these lists are of considerable value, most of the transcripts present are expressed in multiple cell types, so that identifying Leydig cell-specific transcripts can be complex. A recent alternative method has been developed to analyse transcripts in ribosomes specific to the Leydig cells and through this to identify transcripts enriched in the Leydig cell population (Sanz *et al.* 2013). In this study, we have taken a different complementary approach – in order to identify genes specifically expressed in the adult Leydig cell population, we used the cytotoxic agent ethane dimethane sulphonate (EDS). In adult rats, a single injection of EDS leads to rapid (mostly within 24 h) and complete ablation of the adult Leydig cell population (Kerr *et al.* 1985, Morris *et al.* 1986). Using microarrays, we followed the changes in testis mRNA transcript levels after EDS

injection in order to identify specific transcript species that are markedly reduced over the period of Leydig cell ablation. A potentially confounding factor when using the standard EDS model for this purpose would be the related degeneration of the androgen-dependent spermatogenic epithelium following EDS treatment. To circumvent this problem, we have recently refined the EDS model using butane dimethane sulphonate (busulphan) to generate a germ cell-free testis, which can be used to study Leydig cell ablation in comparative isolation (O'Shaughnessy *et al.* 2008a). Results from the microarray and post-array analyses suggest that the Leydig cells are likely to play a role in protecting the testis from xenotoxicant action along with their established steroidogenic function.

Materials and methods

Synthesis of EDS

EDS is not commercially available and has previously been synthesised as described by Jackson & Jackson (1984). For this study, a novel preparation method was used: ethylene glycol (10 g, dry) was mixed slowly with methane sulphonyl chloride (16 ml) in a flask cooled in ice. Triethylamine (40 ml) was then added dropwise with constant stirring to the cooled mixture, which will turn semisolid. The reaction mixture was allowed to stand at 15–20 °C for 2–3 h and a mixture of concentrated sulphuric acid (40 ml) and crushed ice (500 ml) was carefully prepared in a separate vessel. Small amounts of this ice-cold mixture were titrated slowly into the main reaction vessel until excess triethylamine was neutralised and EDS appeared as white crystals. EDS will become a viscous liquid if the mixture is allowed to warm up. The crystals were filtered and washed with ice-cold water, then recrystallised from hot (55 °C) methanol.

Animals and animal treatments

Adult Sprague–Dawley rats (250–300 g) were purchased from Harlan UK (Bicester, Oxon, UK). The germ cell population was ablated as described previously (O'Shaughnessy *et al.* 2008a) by two injections (i.p.) of busulphan (10 mg/kg) spaced 4 weeks apart. Six weeks after the second injection of busulphan, the animals were injected (i.p.) with EDS (100 mg/kg) or vehicle. Animals (3–5 per group) were killed by CO₂ inhalation at 1, 3, 5, 8, 12 and 20 days after EDS treatment. Control animals were injected with only vehicle. For developmental studies, rats were bred in-house and normal, untreated animals killed on days 1, 2, 4, 5, 7, 10, 12, 14, 17, 20 and 90 (adult). In all cases, one testis from each animal was processed immediately for RNA extraction while the other testis was weighed, cut in half and one half fixed in Bouin's solution while the other half was frozen rapidly in liquid N₂ and stored at –20 °C. All animal procedures were carried out under UK Home Office licence and with local ethical approval.

RNA extraction

To extract RNA, whole testes were homogenised in TRIzol (Invitrogen Ltd). In studies designed to measure transcript

expression through real-time PCR, luciferase mRNA (Promega UK) was added to the samples at the time of RNA extraction and subsequently used as an external standard in real-time assays (Baker & O'Shaughnessy 2001b, Johnston *et al.* 2004). For array studies, the RNA was further processed using RNeasy kits (Qiagen Ltd) according to the manufacturer's instructions.

Microarray

The quality of the RNA was assessed with an Agilent RNA bioanalyser and samples of 10 µg total RNA were reverse transcribed and then *in vitro* transcribed according to the Affymetrix standard protocols. The Affymetrix (Affymetrix, Santa Clara, CA, USA) rat genome 230 2.0 arrays were used in all hybridisations.

Quantitative PCR

Extracted RNA was reverse transcribed using random hexamers and Moloney murine leukaemia virus reverse transcriptase (Superscript II, Invitrogen Ltd) as described previously (O'Shaughnessy & Murphy 1993, O'Shaughnessy & Mannan 1994). Transcript levels were measured by real-time PCR using the SYBR green method with a Stratagene MX3000 cyclor (O'Shaughnessy & Murphy 1993, O'Shaughnessy *et al.* 2008b). Levels of transcript were expressed relative to the level of the external luciferase control or against the housekeeping gene *Sdha*. Measurement relative to an external standard allows transcript levels to be expressed on a per testis basis and this method was used for developmental studies while expression relative to an internal housekeeping gene was used to compare expression with array data (Baker & O'Shaughnessy 2001b, Baker *et al.* 2003b). All primers were designed using Primer Express 2.0 (Applied Biosystems) with parameters described previously (Czechowski *et al.* 2004).

Immunohistochemistry

Testes were fixed overnight in Bouin's solution and stored in 70% ethanol. Wax sections (5 µm) were incubated with primary antibody overnight at 4 °C and endogenous biotin was blocked using an avidin/biotin blocking kit (R&D Systems Europe Ltd, Abingdon, UK). The antibodies used were CYP11A1 (anti-rabbit, gift from Dr A H Payne, University of Stanford, USA), (CES3) (sc-82555, Santa Cruz Biotechnology, Inc.), AQP9 (AQP91-A, Autogen Bioclear UK Ltd, Wiltshire, UK), CXCL12 (MAB350, R&D Systems Europe Ltd) and EH (gift from Prof. Dr Ulrich M Zanger, Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Germany). The sections were washed and incubated for 30 min with biotinylated secondary antibody (R&D Systems Europe Ltd). Bound primary antibody was detected using a peroxidase-conjugated secondary antibody, followed by a fluorescein-tyramide amplification step with visualisation using 3,3'-diaminobenzidine tetrahydrochloride (Dako UK Ltd, Cambridgeshire, UK). For negative-control samples, non-immune serum replaced primary antiserum.

Statistical analysis

Microarray data from two independent samples from animals killed at 0, 1, 3, 5, 8 and 12 days after EDS treatment were analysed initially by the robust multichip average method using the BioConductor microarray analysis software (Irizarry *et al.* 2003), while differentially expressed genes were identified using RankProducts (Breitling *et al.* 2004). Transcripts were considered to show a significant change if signal strength at one time point after EDS treatment was >100 and there was an overall false discovery rate (FDR) $<5\%$ considering all time points and/or a more than twofold difference in expression at a single time point with FDR $<10\%$. Database and spreadsheet comparisons were carried out using a relational database (Access, Microsoft Corp.). Further analysis of potential interactions between transcripts was partly carried out using Ingenuity Pathways Analysis (www.ingenuity.com), Build version: 220217 with relationships included where experimentally confirmed. Data from real-time PCR studies were analysed by single-factor ANOVA followed by Fisher's multiple comparison test (Minitab, Minitab, Inc.). Where necessary, data were log-transformed before analysis to remove heterogeneity of variance.

Results

Effects of EDS

Changes in testis histology and testosterone levels following EDS treatment in this model have been described previously (O'Shaughnessy *et al.* 2008a).

Identification of Leydig cell transcripts

Following ablation of Leydig cells by EDS treatment of germ cell-free rats, there was a significant change in the levels of 2200 transcripts over a 12-day period (Supplementary Table 1, see section on supplementary data given at the end of this article). Of these, 1103 transcripts were consistently reduced in expression at all time periods. It might be expected that most of the transcripts that show a marked and sustained decline in expression after EDS treatment will be of a Leydig cell origin although a number will be androgen dependent transcripts expressed in other somatic cells. In addition, transcripts that are expressed in Leydig cells and in at least one other cell type will decline after EDS treatment as the Leydig cells are ablated, but the overall decline will be less marked. In order to identify genes that are most likely to be Leydig cell specific, parameters were set based on the expression of canonical Leydig cell-specific transcripts. Changes in transcript levels of some of these known Leydig cell genes following EDS treatment are shown in Fig. 1A and confirm the expected rapid loss of transcripts. To identify other Leydig cell-specific transcripts, the following constraints, based on the canonical transcripts, were applied: i) levels must have reduced by 40% or more during the first 24 h after EDS treatment; ii) transcript levels must have

Figure 1 Microarray data showing relative changes in expression of known and putative Leydig cell transcripts. (A) Expression data from eight Leydig cell-specific transcripts following EDS treatment. The transcripts were *Hsd3b*, *Cyp17a1*, *Cyp11a1*, *Lhcgr*, *Insl3*, *Hsd17b3*, *Gnhr*, *Hmgcs2*. (B) Expression data from 93 putative Leydig cell transcripts shown in Supplementary Table 2. Individual transcripts are shown with a grey line and the mean value is shown in black.

fallen below 20% of control within 5d and iii) average levels between 3d and 8d after EDS treatment must have been below 30% of control. While these constraints are arbitrary, they were carefully designed specifically to include known Leydig cell-specific transcripts. Overall, 93 transcript species fulfilled these criteria, including the major steroidogenic enzymes, the luteinizing hormone (LH) receptor and insulin-like growth factor 3 (*Insl3*) but excluding *Star* (discussed below). Expression changes in these 93 transcripts are shown in Fig. 1B and the top 25 genes are listed in Table 1 in ascending order of expression on day 3 after EDS treatment. The nearer to the top that a transcript appears in Table 1, therefore, the lower the relative expression on day 3 after EDS treatment and the more likely it is to be specifically expressed in the Leydig cell. The complete list of 93 transcripts is shown in Supplementary Table 2.

Comparison to other testicular cell transcript databases

Microarray analysis of transcripts from isolated adult rat Leydig cells by Stanley *et al.* (2011) showed the presence of 16 713 specific species (not allowing for duplicates on

Table 1 Top 25 genes identified as Leydig cell specific.

Affymetrix	GenBank	Symbol	Gene	Control (raw expression)	Expression (per cent control) after EDS treatment				
					1d	3d	5d	8d	12d
1387139_at	NM_032082	<i>Hao2</i>	Hydroxyacid oxidase 2 (long chain)	9678	5.33	0.45	0.31	0.30	0.31
1387034_at	NM_012619	<i>Pah</i>	Phenylalanine hydroxylase	4450	8.02	0.61	0.54	0.58	0.56
1387123_at	NM_012753	<i>Cyp17a1</i>	Cytochrome P450, family 17a1	6904	8.19	0.63	0.54	1.73	6.65
1370363_at	L46791	^a <i>Ces3/Ces1d</i>	Carboxylesterase 3 (1d)	10 226	15.24	0.74	0.47	0.49	0.71
1388241_at	AF139918	<i>Ins13</i>	Insulin-like 3	10 447	17.39	0.98	0.65	0.67	0.82
1368578_at	NM_017265	<i>Hsd3b1</i>	Hydroxysteroid dehydrogenase-1, Δ 5-3 β	5826	8.52	1.28	1.09	2.95	11.78
1368468_at	NM_017286	<i>Cyp11a1</i>	Cytochrome P450, family 11a1	4896	9.70	1.36	1.26	2.85	7.01
1370964_at	BF283456	<i>Ass1</i>	Arginosuccinate synthetase	6673	19.45	1.57	1.17	1.42	2.53
1370148_at	NM_012582	<i>Hp</i>	Haptoglobin	7192	12.24	1.88	1.75	1.65	1.65
1388176_at	AI717047	<i>Cml5</i>	Camello-like 5	1194	2.08	2.74	2.77	2.61	2.87
1370065_at	NM_053318	<i>Hpx</i>	Haemopexin	2648	9.06	3.02	2.30	2.11	2.23
1368621_at	NM_022960	<i>Aqp9</i>	Aquaporin 9	2907	5.53	3.02	2.16	3.17	3.04
1378133_at	AW532618	<i>Slc7a11</i>	Solute carrier family 7, member 11	1967	25.36	3.29	3.45	4.60	7.43
1387465_a_at	NM_031038	<i>Gnrhr</i>	Gonadotrophin-releasing hormone receptor	1043	6.25	4.26	3.87	3.87	4.03
1387423_at	NM_012978	<i>Lhcgr</i>	Luteinizing hormone/choriogonadotrophin receptor	615	5.95	4.69	4.25	4.31	5.10
1387973_at	U39206	<i>Cyp4f4</i>	Cytochrome P450, family 4f4	678	9.44	5.42	5.59	6.19	5.51
1385500_at	BF400284	<i>LOC500945</i>	Similar to 1700012B09 Rn.59584	758	9.77	5.82	3.86	6.96	10.79
1369136_at	NM_012542	<i>Cyp2a3</i>	Cytochrome P450, subfamily IIA3	501	8.78	5.99	6.39	6.19	5.59
1392664_at	BF551274	<i>Gpr182</i>	G protein-coupled receptor 182 (adrenomedullin receptor)	466	5.79	6.01	5.58	6.01	7.08
1368990_at	NM_012940	<i>Cyp1b1</i>	Cytochrome P450, family 1b1	7824	5.92	6.02	3.59	5.52	7.39
1367857_at	NM_053445	<i>Fads1</i>	Fatty acid desaturase 1	5010	12.75	6.85	2.99	6.39	14.85
1367689_a_at	AF072411	<i>Cd36</i>	CD36 molecule	5232	7.15	7.39	10.25	7.44	5.31
1388037_at	J05087	<i>Atp2b3</i>	ATPase, Ca++ transporting, plasma membrane 3	759	8.72	7.48	12.37	10.50	8.19
1381920_at	AI502118		Transcribed locus	634	9.89	7.65	6.91	7.61	7.53
1371100_at	AA859049	<i>Ces1c</i>	Carboxylesterase 1C	712	12.64	7.72	6.46	7.02	8.71

^aRat *Ces1d* was previously called *Ces3* and is orthologous to mouse *Ces3* (Holmes *et al.* 2010).

the arrays). Most of these transcripts will not be unique to the Leydig cells, but a degree of specificity can be estimated by determining the relative enrichment of these transcripts in comparison to our control whole-testis arrays. If a transcript shows some specificity to the Leydig cells (i.e. it is expressed at a higher level in the Leydig cells than in other cells), it would be expected that relative expression in the Leydig cell arrays would be higher than the whole-testis arrays. Comparing all transcripts in the Leydig cell array with the whole-testis arrays, the median ratio of (Leydig cell):(whole-testis) transcript expression was 0.25, so that any value above this would be consistent with at least some specific localisations in the Leydig cells. The average ratio for all 93 transcripts in [Supplementary Table 2](#) is 1.03 (median 0.86) and only three have a ratio <0.25. This is consistent with a predominant Leydig cell expression of transcripts listed in [Table 1](#). Stanley *et al.* (2011) also identified

42 genes upregulated during Leydig cell development and, of these genes, 17 are also included in [Supplementary Table 2](#), including eight of the top 11 genes we identified. When the same 42 genes identified by Stanley (2011) were compared with the full list of transcripts significantly altered by EDS ([Supplementary Table 1](#)), the number of matches increased to 23 although most of the additional six matches showed either low expression or complex changes in expression after EDS treatment ([Supplementary Table 3](#), see section on [supplementary data](#) given at the end of this article).

A recent report which analysed the Leydig and Sertoli 'translatome' (polysome-associated mRNAs) has identified 2608 transcripts, which are enriched in mouse Leydig cells (Sanz *et al.* 2013). Comparison of genes in [Supplementary Table 2](#) with those identified as Leydig cell specific by Sanz *et al.* (2013) showed that just over half of [Supplementary Table 2](#) (55%) appears in both

databases. More surprisingly, of the top 50 transcripts identified as Leydig cell specific by Sanz *et al.* (2013), only 18 were significantly altered by EDS treatment (Supplementary Table 4, see section on supplementary data given at the end of this article) and only six met the criteria for inclusion in Supplementary Table 2 of this study. Expanding the examination to include all 2608 genes in the Sanz *et al.* (2013) dataset identified 300 genes that are also included in Supplementary Table 1. Many of these 300 genes, however, showed no consistent and marked decline in expression after EDS treatment (Supplementary Table 5, see section on supplementary data given at the end of this article).

Transcript expression in isolated rat Sertoli cells and germ cells, measured using microarrays, has been described by Johnston *et al.* (2008). In order to compare these databases with the putative Leydig cell transcripts described here, the ratio of Sertoli cell or germ cell expression to whole-testis expression was determined for each transcript. As with the Leydig cell arrays from Stanley *et al.* (2011) described above, this then serves as a measure of the likelihood of that transcript showing higher-/lower-than-average expression in those cells. Comparing all 31 000 transcripts on the arrays, the median ratios for transcript expression in Sertoli cells, round spermatids, pachytene spermatocytes and combined spermatogonia plus early spermatocytes relative to the whole testis were 0.74, 0.96, 1.01 and 1.18 respectively. Values for each of the putative Leydig cell genes are shown in Supplementary Table 2. With respect to round spermatids and pachytene spermatocytes, most of the Leydig cell transcripts listed in Supplementary Table 2 had values less than the median suggesting low to very low levels of expression in these cell types. A small number of transcripts (e.g. *Rab33a* and *Tekt3*) showed expression ratios higher than the median for one or both germ cell types making it likely that these transcripts are expressed in both Leydig cells and germ cells. With respect to array data from Sertoli cells and combined spermatogonia plus early spermatocytes, many of the Leydig cell transcripts in Supplementary Table 2 showed expression ratios greater, and in some cases markedly greater, than the median. This included canonical Leydig cell genes such as *Hsd3b1*, *Cyp17a1* and *Cyp11a1*, suggesting that the isolated Sertoli cells and combined spermatogonia plus early spermatocytes used to generate the arrays contained a significant number of Leydig cells. This means, unfortunately, that the calculated ratios are not helpful in assessing likely transcript expression in these particular cell types.

Real-time PCR of transcript levels after EDS treatment

To confirm the array data shown in Table 1, the expression of selected transcripts following EDS treatment was measured by real-time PCR (Fig. 2). The data in Fig. 2A shows the expression pattern of three

individual canonical Leydig cell-specific transcripts. Comparison of these with the putative Leydig cell transcripts in Fig. 2B confirms the same general pattern of expression after EDS treatment. The major difference between Fig. 2A and B is that some of the transcripts in Fig. 2B have higher levels of residual transcript remaining after EDS treatment, which probably indicates the presence of some low expression in other testicular cell types. Changes in *Star* transcript levels are shown in Fig. 2C. This gene might have been expected to have the same pattern of expression as other canonical Leydig cell genes in Fig. 2A but shows, instead, a gradual decline in transcript levels whether measured by array or real-time PCR. Also shown in Fig. 2C is *Tbp* which is a ubiquitous cellular transcript and serves as a positive control. It should be noted that in all cases there was good correlation between data from arrays and real-time PCR.

To measure the recovery of transcript levels as the Leydig cells regenerate following EDS treatment, samples were taken 20d after treatment and expression of the transcripts shown in Fig. 2 was compared with controls by real-time PCR (Fig. 3). Levels of the canonical transcripts *Cyp11a1*, *Hsd3b* and *Cyp17a1* returned to normal or close to normal by day 20 as suggested previously (O'Shaughnessy *et al.* 2008a). Expression of the other putative Leydig cell transcripts showed some recovery by day 20 after EDS treatment, but all remained clearly lower than control levels.

Developmental changes in Leydig cell transcripts

The slow recovery of transcript levels shown in Fig. 3 suggested that many of the putative Leydig cell transcripts identified in Table 1 may be expressed relatively late in Leydig cell development. To examine this possibility, and to determine if any of the transcripts are specific only to the 'adult' population of Leydig cells, transcript levels were measured by real-time PCR relative to an external standard during development in normal rats after birth (Fig. 4). Canonical Leydig cell transcripts were detectable at all ages and either reached adult levels by 20 days (*Hsd3b* and *Cyp17a1*) or were within 50% of adult levels at that age (*Cyp11a1*). Most of the putative Leydig cell transcripts were also detectable at all ages but expression at 20d was <10% of adult levels in most cases indicating late onset of expression. One transcript, *Pah*, was largely undetectable before 20d (Fig. 4), indicating that it is expressed only in the adult Leydig cells. Expression of *Ces1d* was unusual as it showed a small peak of activity at day 7, then declined to undetectable levels at day 17 before increasing again at puberty.

Immunohistochemistry

Localisation of proteins from selected genes in Table 1 was determined by immunohistochemistry using normal adult

Figure 2 Comparison of microarray data from selected transcripts with results from real-time PCR. Transcript levels were measured in adult rat testis after EDS treatment using microarrays or by real-time PCR, expressed relative to an internal housekeeping gene *Sdha*. Results show the mean of duplicate animals used at each point for array studies and three to five animals used for real-time PCR. The transcripts are divided into those recognised as canonical Leydig cell transcripts (A), putative Leydig cell transcripts in [Supplementary Table 2](#) (B) and others (C) which include the positive-control *Tbp*.

rat testes ([Fig. 5](#)). Results show that CES1D and AQP9, both ranked highly in [Table 1](#), are clearly expressed in the Leydig cells with little or no expression in other cell types. EPHX1, which is ranked towards the bottom of [Table 1](#), is

also predominantly expressed in the Leydig cells although low levels of expression were also seen in some elongating spermatids ([Fig. 5](#)). One of the more surprising transcripts in [Table 1](#) and [Supplementary Table 2](#) is *Cxcl12* which has

Figure 3 Recovery of transcript expression following EDS treatment. Transcript levels were measured by real-time PCR 20 days after EDS treatment. Mean expression ($n=3$), relative to control (non-treated) values is shown. Three canonical Leydig cell genes are highlighted by a grey box.

previously been reported to be expressed predominantly in the mouse Sertoli cell (Gilbert *et al.* 2009, Payne *et al.* 2010, Yang *et al.* 2013). Immunohistochemistry shows, however, that this chemokine is expressed only in the interstitial tissue and mainly in the Leydig cells in the control adult rat testis with some expression also in endothelial cells. Expression of CYP11A1 in the adult Leydig cells is also shown in Fig. 5 as a positive control.

Discussion

The Leydig cells are part of an integrated cellular system in the testis that ensures male fertility. While the primary function of the Leydig cells is to secrete androgen, it is likely that they also play other roles in the maintenance of testicular homeostasis and optimisation of male reproduction. Previous studies have shown that Leydig cells synthesise several enzymes and growth factors not directly involved in steroidogenesis. These include INSL3 (Pusch *et al.* 1996), inhibin/activin subunits (Roberts *et al.* 1989), PTGDS (Baker & O'Shaughnessy 2001a), NUCB2 (Garcia-Galiano *et al.* 2012), epoxide hydrolase and glutathione *S*-transferases (Ishii-Ohba *et al.* 1984, Collier *et al.* 2001), indicating a number of different activities that may be associated with the cells. To gain a detailed understanding of all aspects of Leydig cell function both within the context of the testis and systemically, however, it is necessary to establish a list of genes/proteins expressed specifically in these cells. This process has already begun (Stanley *et al.* 2011, Sanz *et al.* 2013) and results from the present study both confirm and challenge the previous findings and extend the likely repertoire of Leydig cell activity.

The Leydig cell transcriptome and/or Leydig cell-specific transcripts have been described recently using microarrays of purified isolated cells or by looking for

transcript enrichment in Leydig cell-specific ribosomes. Stanley *et al.* (2011) have used cell isolation techniques, followed by microarrays, to identify the transcripts in adult rat Leydig cells at different stages of development. This technique provides a global view of cell transcript expression although the quality of the resultant data is dependent upon the purity of the isolated cells and the effects of the isolation technique on transcript expression. As the transcriptome of these cells contains over 16 000 different transcript species, it is important to use filtering techniques being able to identify genes of interest and this was achieved using a developmental approach. The strategy used by Sanz *et al.* (2013) avoided the necessity for cell isolation and generated a Leydig cell transcriptome using an *in vivo* ribosome tagging technique which allowed polysome-associated mRNAs from Leydig cells to be characterised. Identification of Leydig cell-specific transcripts was achieved by determining relative enrichment compared with total input mRNAs. This approach is extremely powerful if the *Cre* promoter used is specific to the cell of interest and in this case the *Cyp17iCre* was shown to be largely expressed in the Leydig cells although some tubular expression was also seen. The EDS-induced cell ablation approach used in this study also does not rely on cell isolation techniques and offers the advantage of being able to identify transcripts largely or exclusively expressed in the cell of interest. There are, however, a number of caveats with this approach that should be identified. First, as the germ cell population was ablated to allow a more robust analysis of the array data, it is possible that some of the transcripts are also expressed in germ cells although comparison to germ cell arrays from Johnston *et al.* (2008) would suggest that this number of transcripts is small (Supplementary Table 2). There is also the potential for off-target, secondary effects on other cells which might confuse the analysis. Prior ablation of the germ cells with busulphan, which does not significantly affect Leydig cell activity (O'Shaughnessy *et al.* 2008b), removed the most androgen-dependent cell population from the testis but significant changes in the remaining Sertoli cells and PTMCs would still be expected following the loss of androgen stimulation. However, any reduction in expression in these cells might be expected to be delayed, and it should be noted that expression of *Rhox5*, *Cldn11*, *Drd4* and *Eppin*, putative androgen-dependent transcripts in the mouse (Lindsey & Wilkinson 1996, O'Shaughnessy *et al.* 2007, Hu *et al.* 2010, Willems *et al.* 2010), did not show any change up to 20d following EDS treatment (not shown). In contrast, *Tubb3* and *Cyp26b1*, also proposed to be androgen dependent in the mouse (O'Shaughnessy *et al.* 2007, Willems *et al.* 2010), did show reduced expression after EDS treatment but with complex patterns of change, quite distinct from the canonical Leydig cell genes (Supplementary Table 1). Discrepancies between the published literature and the effects of EDS on these

Figure 4 Developmental changes in Leydig cell transcripts. Testicular transcript levels were measured in rats of different ages relative to an external standard (luciferase). The mean $\pm$ S.E.M. of between three and five animals per group is shown for canonical Leydig cell genes (A) and putative Leydig cell genes (B). ND, not detectable.

androgen-dependent transcripts may be due to species differences between rat and mouse (see below) or to other differences in the animal models used (e.g. altered androgen sensitivity in Sertoli cells following germ cell ablation). One last potential weakness of this technique is the possibility that EDS has direct effects on other cell types in the testis leading to alterations in specific transcript levels. This possibility cannot be ruled out although EDS is largely cleared from the testis within 24 h (Edwards *et al.* 1969), and it might be expected that

transcript levels would tend to revert back towards normal (and so not be included in Table 1) unless a more permanent change had occurred in the target cell.

It is of interest that there are distinct differences in the lists of Leydig cell transcripts produced by the three experimental approaches described above. Best agreement is between the study of Stanley *et al.* (2011) and the current study with over 40% of the developmentally regulated Leydig cell genes also appearing in Table 1. This includes most of the top-ranked transcripts in

Figure 5 Expression of selected proteins in the adult rat testis. Testes from normal (untreated) adult rats were fixed in Bouin's solution and immunohistochemistry was used to localise expression. In each case, the proteins were localised exclusively or predominantly in the interstitial tissue. The insert to CYP11A1 shows a control without primary antibody. Another control is shown as an insert to CXCL12 as the primary antibody in this case was raised in mouse. No cross-reactivity to the secondary antibody was seen.

Table 1, providing further confidence that these are Leydig cell-specific transcripts. Failure of the remaining 60% of developmentally regulated Leydig cell genes identified by Stanley *et al.* (2011) to show a significant change in expression after EDS treatment indicates that they are not specific to the Leydig cells in the testis and are probably also expressed elsewhere. The relative lack of overlap between the transcripts identified by Sanz *et al.* (2013) is most likely to be due to species differences, possible non-Leydig cell *Cre* expression in the *Cyp17iCre* mice and androgen-dependent changes in some non-Leydig cell transcripts following EDS treatment. Differences in the transcriptome between rats and mice will account for some variation – for example, *Cyp4f4*, *Cyp2a3* and *Cyp2t1* listed in Table 1 are specific to the rat genome, while four of the ten most highly enriched Leydig cell genes described in the study of Sanz *et al.* (2013) are specific to the mouse genome. There are also some known differences in Leydig cell function between the species (e.g. *Gnrhr* is expressed in the rat testis but not the mouse testis (Ishaq *et al.* 2013)), while a number of mouse transcripts in the Sanz *et al.* (2013) study showed low expression in the rat arrays so that any effect of EDS would be difficult to show (e.g. *Fetub*). Finally, it has been shown that elimination of Leydig cells by EDS can induce transcript expression by other cell types such

as the Sertoli cells (Garcia-Galiano *et al.* 2012), so that these transcripts would not be identified as normally Leydig cell specific using the cell ablation technique described here.

The method/algorithm used in this study to identify Leydig cell transcripts was based on changes in expression of known canonical Leydig cell genes, such as *Cyp11a1* and *Hsd3b*, although three known Leydig cell transcripts, *Star*, *Ptgds* and *Sult1e1*, did not fit the pattern. The STAR protein is an essential component of the steroid biosynthesis pathway (Clark *et al.* 1994), but the gradual decline in transcript levels following Leydig cell ablation suggests that other testicular cell types must also express *Star*. Earlier studies have shown that *Star* expression can be induced in Sertoli cells by follicle-stimulating hormone (FSH; Gregory & DePhilips 1998), which would be consistent with results reported here as EDS treatment causes a significant increase in circulating FSH levels (Jackson & Morris 1977, Molenaar *et al.* 1986). Previous studies have shown that *Ptgds* and *Sult1e1* are expressed in mouse Leydig cells (Song *et al.* 1997, Baker & O'Shaughnessy 2001b). Levels of *Ptgds* declined after EDS treatment in this study, but only to about 50–60% of control (not shown), so that it did not fit the criteria for inclusion in Table 1. This would suggest that *Ptgds* is expressed in adult rat Leydig cells and, probably, also in another cell type. Expression of *Sult1e1* was not detectable above background levels in any of the arrays in this study, suggesting that it is not expressed in the rat testis which would be consistent with the absence of identified expressed sequence tags in the rat testis (Unigene Rn.32104).

Proteins encoded by the transcripts listed in Supplementary Table 2 function in a variety of roles as detailed in Supplementary Figure 1, (see section on supplementary data given at the end of this article). Apart from canonical functions in steroid synthesis and metabolism, the most prominent functional group is involved in drug and xenotoxicant metabolism. This includes 15 of the 93 Leydig cell-specific transcripts in Table 1 and suggests that the Leydig cells may have significant capacity to protect the testis from exposure to harmful exogenous or endogenous agents. Previous studies have shown that the testes of various species show metabolic enzyme activity associated with carboxylesterase, CYP1B1, epoxide hydrolase and glutathione S-transferase, and the Leydig cells are likely, both from the previous work and from results reported here, to be the major contributors to this activity (Blackshaw 1970, DiBiasio *et al.* 1991, Otto *et al.* 1992, Ellis *et al.* 1998, Chen *et al.* 2004). A number of xenotoxicants have been shown to have selective reproductive toxicity in the rat (e.g. bisphenol A, phthalates, polyaromatic hydrocarbons, molinate) acting primarily on the Sertoli cells (Boekelheide *et al.* 2005) and Leydig cells (Ellis *et al.* 1998, Papadopoulos 2007) and leading to disruption of spermatogenesis. Xenobiotic metabolism by the Leydig cells may act to limit and reduce the effects of these, and other, compounds as

suggested previously (DiBiasio *et al.* 1991). In addition to metabolic enzymes, the Leydig cells appear to secrete a number of active proteins such as haemopexin, haptoglobin and lactoperoxidase. Haptoglobin and haemopexin are acute-phase proteins typically secreted by the liver as a stress response (Guillouzo *et al.* 1984) though they are also secreted by other organs in response to acute injury (Zager *et al.* 2012). Both will act to reduce oxidative stress through antioxidant action or through haem binding (Tseng *et al.* 2004, Tolosano *et al.* 2010), while haemopexin also has potent anti-inflammatory effects (Fink 2009). Lactoperoxidase, in contrast, is a natural antibacterial agent usually associated with exocrine glands (Pruitt & Reiter 1985). While these proteins have diverse actions, one functional link is that they would act to protect testicular function. Allied to the expression of metabolic enzymes by the Leydig cells, this suggests that a major function of the Leydig cells may be to maintain testicular function in the face of diverse potential challenges. Earlier studies, using an androgen-supplemented EDS rat model, reported that testosterone is the only product of the Leydig cell essential for spermatogenesis (Sharpe *et al.* 1988). It would now be of interest to determine whether spermatogenesis in the absence of Leydig cells is more susceptible to the effects of xenotoxins or other systemic challenges given the likely protective role played by these cells.

Results from this study show that the chemokine CXCL12 is expressed primarily in the Leydig cells of the adult rat testis with no expression apparent in the tubules. This is surprising as previous studies have reported that CXCL12 is produced by the Sertoli cells in the mouse testis and that it is required for migration of the primordial germ cells (PGC) to the tubules and for maintenance of the PGC and spermatogonial stem cells in the Sertoli cell niche (Molyneux *et al.* 2003, Payne *et al.* 2010, Yang *et al.* 2013). However, the EDS and immunohistochemical data from the rat are clear, and differences in reported mouse studies are, presumably, species related. It has been reported that mouse Leydig cells secrete CSF1 which acts to increase SSC self-renewal (Oatley *et al.* 2009), thereby suggesting that the adult Leydig cells may be a major contributor to the SSC niche. However, in our arrays, *Csf1* transcript levels were not altered by EDS treatment, which indicates that it is unlikely to be a Leydig cell product in the rat. Overall, data from this study support the hypothesis that the Leydig cells contribute to the SSC niche although the nature of that support may vary between species.

Results in Table 1 (and Supplementary Figure 1) identify a number of receptors apparently associated with the Leydig cells. Receptors for LH, prolactin and GnRH have all been shown in earlier studies to be expressed in rat Leydig cells (Zhang *et al.* 1995, Ariyaratne *et al.* 2000, Ishaq *et al.* 2013), but others have not been described previously. GPR182 is an adrenomedullin receptor that mediates a cAMP response to the peptide (Kapas *et al.* 1995). Adrenomedullin is

reported to be expressed in Sertoli cells and Leydig cells and to inhibit LH/hCG stimulation of testosterone production by the testis (Li *et al.* 2006, Chan *et al.* 2008) although the effect does not appear to be marked. CD36 is a cellular membrane glycoprotein and a member of the class B scavenger receptor family. Among other things, CD36 acts to facilitate fatty acid and lipoprotein uptake (He *et al.* 2011) and so may contribute to the cellular pool of cholesterol esters. MRAP is essential for trafficking and functional expression of the ACTH receptor MC2R in the adrenal gland (Novoselova *et al.* 2013). MC2R is functionally expressed in foetal Leydig cells in the mouse testis (O'Shaughnessy *et al.* 2003) but not in adult Leydig cells, and there is no evidence of *Mc2r* expression in adult rat Leydig cells from this study. Therefore, the function of MRAP in adult rat Leydig cells is unclear, but MRAP can interact with other melanocortin receptors and it is possible that it may be involved in the functional expression of other GPRs.

Results in Fig. 4 show that transcripts encoding steroidogenic enzymes reach adult levels by about 20 days of age in the rat. Enzyme activity *per se* starts to increase at about the same age in the rat testis (Inano *et al.* 1967, Goldman & Klingele 1974, Payne *et al.* 1977), while circulating androgen levels start to rise between day 20 and 30 (Piacsek & Goodspeed 1978). Interestingly, the non-canonical Leydig cell-specific transcripts that were tested in this study showed both a slow recovery after EDS treatment and a later developmental increase in expression to adult levels. This is consistent with a staged maturation process in the adult Leydig cells described by others (Ge *et al.* 2005, Stanley *et al.* 2011) and suggests that these additional functions may develop to ensure optimal androgen production in adulthood and to protect the developing spermatogenic population.

The Leydig cells are essential regulators of testicular function, fertility and male behaviour. Results from this study identify the key transcripts specifically associated with these cells and show that the main function of the cells, apart from androgen production, is likely to be to protect the testis from toxicant exposure and stress. The approach used also highlights the potential and advantages of using cell ablation to identify cell-specific transcripts.

Supplementary data

This is linked to the online version of the paper at <http://dx.doi.org/10.1530/REP-13-0603>.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding

This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.

Acknowledgements

We thank Prof. Dr Ulrich M Zanger and Prof. A H Payne (deceased) for provision of antibody.

References

- Ariyaratne HB, Mendis-Handagama SM, Hales DB & Mason JI 2000 Studies of the onset of Leydig precursor cell differentiation in the prepubertal rat testis. *Biology of Reproduction* **63** 165–171. (doi:10.1095/biolreprod63.1.165)
- Baker PJ & O'Shaughnessy PJ 2001a Role of gonadotrophins in regulating numbers of Leydig and Sertoli cells during fetal and postnatal development in mice. *Reproduction* **122** 227–234. (doi:10.1530/rep.0.1220227)
- Baker PJ & O'Shaughnessy PJ 2001b Expression of prostaglandin D synthetase during development in the mouse testis. *Reproduction* **122** 553–559. (doi:10.1530/rep.0.1220553)
- Baker PJ, Sha JA, McBride MW, Peng L, Payne AH & O'Shaughnessy PJ 1999 Expression of 3 β -hydroxysteroid dehydrogenase type I and VI isoforms in the mouse testis during development. *European Journal of Biochemistry* **260** 911–916. (doi:10.1046/j.1432-1327.1999.00245.x)
- Baker PJ, Pakarinen P, Huhtaniemi IT, Abel MH, Charlton HM, Kumar TR & O'Shaughnessy PJ 2003a Failure of normal Leydig cell development in follicle-stimulating hormone (FSH) receptor-deficient mice, but not FSH β -deficient mice: role for constitutive FSH receptor activity. *Endocrinology* **144** 138–145. (doi:10.1210/en.2002-220637)
- Baker PJ, Johnston H, Abel MH, Charlton HM & O'Shaughnessy PJ 2003b Differentiation of adult-type Leydig cells occurs in gonadotrophin-deficient mice. *Reproductive Biology and Endocrinology* **1** 4. (doi:10.1186/1477-7827-1-4)
- Blackshaw A 1970 Localisation of testicular enzymes. In *The Testis, II Biochemistry*, pp 94–103. Ed. A Johnson. New York: Academic Press.
- Boekelheide K, Johnson K & Richburg J 2005 Sertoli cell toxicants. In *Sertoli Cell Biology*, pp 345–382. Eds MK Skinner & MD Griswold. Amsterdam: Elsevier.
- Breitling R, Armengaud P, Amtmann A & Herzyk P 2004 Rank products: a simple, yet powerful, new method to detect differentially regulated genes in replicated microarray experiments. *FEBS Letters* **573** 83–92.
- Chan YF, WS O & Tang F 2008 Adrenomedullin in the rat testis. I: its production, actions on testosterone secretion, regulation by human chorionic gonadotropin, and its interaction with endothelin 1 in the Leydig cell. *Biology of Reproduction* **78** 773–779. (doi:10.1095/biolreprod.107.060871)
- Chen H, Irizarry RA, Luo L & Zirkin BR 2004 Leydig cell gene expression: effects of age and caloric restriction. *Experimental Gerontology* **39** 31–43. (doi:10.1016/j.exger.2003.09.021)
- Clark BJ, Wells J, King SR & Stocco DM 1994 The purification, cloning and expression of a novel LH-induced mitochondrial protein in MA-10 mouse Leydig tumor cells. Characterization of the steroidogenic acute regulatory protein (StAR). *Journal of Biological Chemistry* **269** 28314–28322.
- Coller JK, Fritz P, Zanger UM, Siegle I, Eichelbaum M, Kroemer HK & Mürdter TE 2001 Distribution of microsomal epoxide hydrolase in humans: an immunohistochemical study in normal tissues, and benign and malignant tumours. *Histochemical Journal* **33** 329–336. (doi:10.1023/A:1012414806166)
- Czechowski T, Bari RP, Stitt M, Scheible WR & Udvardi MK 2004 Real-time RT-PCR profiling of over 1400 Arabidopsis transcription factors: unprecedented sensitivity reveals novel root- and shoot-specific genes. *Plant Journal* **38** 366–379. (doi:10.1111/j.1365-3113X.2004.02051.x)
- DiBiasio KW, Silva MH, Shull LR, Overstreet JW, Hammock BD & Miller MG 1991 Xenobiotic metabolizing enzyme activities in rat, mouse, monkey, and human testes. *Drug Metabolism and Disposition* **19** 227–232.
- Edwards K, Craig AW, Jackson H & Jones AR 1969 Studies with alkylating esters. I. The fate of ethylene dimethanesulphonate. *Biochemical Pharmacology* **18** 1693–1700. (doi:10.1016/0006-2952(69)90158-0)
- Ellis MK, Richardson AG, Foster JR, Smith FM, Widdowson PS, Farnworth MJ, Moore RB, Pitts MR & Wickramaratne GA 1998 The reproductive toxicity of molinate and metabolites to the male rat: effects on testosterone and sperm morphology. *Toxicology and Applied Pharmacology* **151** 22–32. (doi:10.1006/taap.1998.8371)
- Fink MP 2009 Editorial: hemopexin: newest member of the anti-inflammatory mediator club. *Journal of Leukocyte Biology* **86** 203–204. (doi:10.1189/jlb.0309137)
- Garcia-Galiano D, Pineda R, Ilhan T, Castellano JM, Ruiz-Pino F, Sanchez-Garrido MA, Vazquez MJ, Sangiao-Alvarellos S, Romero-Ruiz A, Pinilla L et al. 2012 Cellular distribution, regulated expression, and functional role of the anorexigenic peptide, NUCB2/nesfatin-1, in the testis. *Endocrinology* **153** 1959–1971. (doi:10.1210/en.2011-2032)
- Ge RS, Dong Q, Sottas CM, Chen H, Zirkin BR & Hardy MP 2005 Gene expression in rat Leydig cells during development from the progenitor to adult stage: a cluster analysis. *Biology of Reproduction* **72** 1405–1415. (doi:10.1095/biolreprod.104.037499)
- Gilbert DC, Chandler I, McIntyre A, Goddard NC, Gabe R, Huddart RA & Shipley J 2009 Clinical and biological significance of CXCL12 and CXCR4 expression in adult testes and germ cell tumours of adults and adolescents. *Journal of Pathology* **217** 94–102. (doi:10.1002/path.2436)
- Goldman AS & Klingele DA 1974 Developmental defects of testicular morphology and steroidogenesis in the male rat pseudohermaphrodite and response to testosterone and dihydrotestosterone. *Endocrinology* **94** 1–16. (doi:10.1210/endo-94-1-1)
- Gregory CW & DePhilips RM 1998 Detection of steroidogenic acute regulatory protein (StAR) in mitochondria of cultured rat Sertoli cells incubated with follicle-stimulating hormone. *Biology of Reproduction* **58** 470–474. (doi:10.1095/biolreprod58.2.470)
- Guillouzo A, Delers F, Clement B, Bernard N & Engler R 1984 Long term production of acute-phase proteins by adult rat hepatocytes co-cultured with another liver cell type in serum-free medium. *Biochemical and Biophysical Research Communications* **120** 311–317. (doi:10.1016/0006-291X(84)91255-5)
- He J, Lee JH, Febbraio M & Xie W 2011 The emerging roles of fatty acid translocase/CD36 and the aryl hydrocarbon receptor in fatty liver disease. *Experimental Biology and Medicine* **236** 1116–1121. (doi:10.1258/ebm.2011.011128)
- Holmes RS, Wright MW, Lauderkind SJ, Cox LA, Hosokawa M, Imai T, Ishibashi S, Lehner R, Miyazaki M, Perkins EJ et al. 2010 Recommended nomenclature for five mammalian carboxylesterase gene families: human, mouse, and rat genes and proteins. *Mammalian Genome* **21** 427–441. (doi:10.1007/s00335-010-9284-4)
- Hu Z, Dandekar D, O'Shaughnessy PJ, De GK, Verhoeven G & Wilkinson MF 2010 Androgen-induced RhoX homeobox genes modulate the expression of AR-regulated genes. *Molecular Endocrinology* **24** 60–75. (doi:10.1210/me.2009-0303)
- Inano H, Hori Y & Tamaoki B 1967 Effect of age on testicular enzymes related to steroid bioconversion. *Ciba Foundation Colloquia on Endocrinology* **16** 105–117.
- Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U & Speed TP 2003 Exploration, normalization, and summaries of high density oligonucleotide array probe level data. *Biostatistics* **4** 249–264.
- Ishaq M, Schang AL, Magre S, Laverriere JN, Guillou A, Coudouel N, Wagnier R, Cohen-Tannoudji J & Counis R 2013 Rat Gnhr promoter directs species-specific gene expression in the pituitary and testes of transgenic mice. *Journal of Molecular Endocrinology* **50** 411–426. (doi:10.1530/JME-12-0231)
- Ishii-Ohba H, Guengerich FP & Baron J 1984 Localization of epoxide-metabolizing enzymes in rat testis. *Biochimica et Biophysica Acta* **802** 326–334. (doi:10.1016/0304-4165(84)90179-X)
- Jackson CM & Jackson H 1984 Comparative protective actions of gonadotrophins and testosterone against the antispermatogenic action of ethane dimethanesulphonate. *Journal of Reproduction and Fertility* **71** 393–401. (doi:10.1530/jrf.0.0710393)
- Jackson CM & Morris ID 1977 Gonadotrophin levels in male rats following impairment of Leydig cell function by ethylene dimethanesulphonate. *Andrologia* **9** 29–35. (doi:10.1111/j.1439-0272.1977.tb01255.x)

- Johnston H, Baker PJ, Abel M, Charlton HM, Jackson G, Fleming L, Kumar TR & O'Shaughnessy PJ 2004 Regulation of Sertoli cell number and activity by follicle-stimulating hormone and androgen during postnatal development in the mouse. *Endocrinology* **145** 318–329. (doi:10.1210/en.2003-1055)
- Johnston DS, Wright WW, DiCandeloro P, Wilson E, Kopf GS & Jelinsky SA 2008 Stage-specific gene expression is a fundamental characteristic of rat spermatogenic cells and Sertoli cells. *PNAS* **105** 8315–8320. (doi:10.1073/pnas.0709854105)
- Kapas S, Catt KJ & Clark AJ 1995 Cloning and expression of cDNA encoding a rat adrenomedullin receptor. *Journal of Biological Chemistry* **270** 25344–25347. (doi:10.1074/jbc.270.43.25344)
- Kerr JB, Donachie K & Rommerts FFG 1985 Selective destruction and regeneration of rat Leydig cells *in vivo*. A new method for the study of seminiferous tubular-interstitial tissue interaction. *Cell and Tissue Research* **242** 145–156. (doi:10.1007/BF00225571)
- Li YY, Hwang IS, WS O & Tang F 2006 Adrenomedullin peptide: gene expression of adrenomedullin, its receptors and receptor activity modifying proteins, and receptor binding in rat testis – actions on testosterone secretion. *Biology of Reproduction* **75** 183–188. (doi:10.1095/biolreprod.106.052274)
- Lindsey JS & Wilkinson MF 1996 *Pem*: a testosterone-regulated and LH-regulated homeobox gene expressed in mouse Sertoli cells and epididymis. *Developmental Biology* **179** 471–484. (doi:10.1006/dbio.1996.0276)
- Molenaar R, de Rooij DG, Rommerts FFG & van der Molen HJ 1986 Repopulation of Leydig cells in mature rats after selective destruction of the existent Leydig cells with ethylene dimethane sulfonate is dependent on luteinizing hormone and not follicle-stimulating hormone. *Endocrinology* **118** 2546–2554. (doi:10.1210/endo-118-6-2546)
- Molyneux KA, Zinsner H, Kunwar PS, Schaible K, Stebler J, Sunshine MJ, O'Brien W, Raz E, Littman D, Wylie C *et al.* 2003 The chemokine SDF1/CXCL12 and its receptor CXCR4 regulate mouse germ cell migration and survival. *Development* **130** 4279–4286. (doi:10.1242/dev.00640)
- Morris ID, Phillips DM & Bardin CW 1986 Ethylene dimethanesulfonate destroys Leydig cells in the rat testis. *Endocrinology* **118** 709–719. (doi:10.1210/endo-118-2-709)
- Nef S, Shipman T & Parada LF 2000 A molecular basis for estrogen-induced cryptorchidism. *Developmental Biology* **224** 354–361. (doi:10.1006/dbio.2000.9785)
- Novoselova TV, Jackson D, Campbell DC, Clark AJ & Chan LF 2013 Melanocortin receptor accessory proteins in adrenal gland physiology and beyond. *Journal of Endocrinology* **217** R1–R11. (doi:10.1530/JOE-12-0501)
- Oatley JM, Oatley MJ, Avarbock MR, Tobias JW & Brinster RL 2009 Colony stimulating factor 1 is an extrinsic stimulator of mouse spermatogonial stem cell self-renewal. *Development* **136** 1191–1199. (doi:10.1242/dev.032243)
- O'Shaughnessy PJ & Mannan MA 1994 Development of cytochrome P-450 side chain cleavage mRNA levels in neonatal ovaries of normal and hypogonadal (*hpg*) mice. *Molecular and Cellular Endocrinology* **104** 133–138. (doi:10.1016/0303-7207(94)90115-5)
- O'Shaughnessy PJ & Murphy L 1993 Cytochrome P-450 17 α -hydroxylase protein and mRNA in the testis of the testicular feminized (*Tfm*) mouse. *Journal of Molecular Endocrinology* **11** 77–82. (doi:10.1677/jme.0.0110077)
- O'Shaughnessy PJ, Willerton L & Baker PJ 2002 Changes in Leydig cell gene expression during development in the mouse. *Biology of Reproduction* **66** 966–975. (doi:10.1095/biolreprod.66.4.966)
- O'Shaughnessy PJ, Fleming LM, Jackson G, Hochgeschwender U, Reed P & Baker PJ 2003 Adrenocorticotrophic hormone directly stimulates testosterone production by the fetal and neonatal mouse testis. *Endocrinology* **144** 3279–3284. (doi:10.1210/en.2003-0277)
- O'Shaughnessy PJ, Abel M, Charlton HM, Hu B, Johnston H & Baker PJ 2007 Altered expression of genes involved in regulation of vitamin A metabolism, solute transportation, and cytoskeletal function in the androgen-insensitive *tfm* mouse testis. *Endocrinology* **148** 2914–2924. (doi:10.1210/en.2006-1412)
- O'Shaughnessy PJ, Morris ID & Baker PJ 2008a Leydig cell re-generation and expression of cell signaling molecules in the germ cell-free testis. *Reproduction* **135** 851–858. (doi:10.1530/REP-07-0529)
- O'Shaughnessy PJ, Hu L & Baker PJ 2008b Effect of germ cell depletion on levels of specific mRNA transcripts in mouse Sertoli cells and Leydig cells. *Reproduction* **135** 839–850. (doi:10.1530/REP-08-0012)
- Otto S, Bhattacharyya KK & Jefcoate CR 1992 Polycyclic aromatic hydrocarbon metabolism in rat adrenal, ovary, and testis microsomes is catalyzed by the same novel cytochrome P450 (P450RAP). *Endocrinology* **131** 3067–3076.
- Papadopoulos V 2007 Environmental factors that disrupt Leydig cell steroidogenesis. In *Leydig Cell in Health and Disease*, pp 393–413. Eds AH Payne & MP Hardy. Totowa: Humana Press.
- Payne AH, Kelch RP, Muroto EP & Kerlan JT 1977 Hypothalamic, pituitary and testicular function during sexual maturation of the male rat. *Journal of Endocrinology* **72** 17–26. (doi:10.1677/joe.0.0720017)
- Payne CJ, Gallagher SJ, Foreman O, Dannenberg JH, Depinho RA & Braun RE 2010 *Sin3a* is required by Sertoli cells to establish a niche for undifferentiated spermatogonia. Germ cell tumors, and spermatid elongation. *Stem Cells* **28** 1424–1434. (doi:10.1002/stem.464)
- Piacsek BE & Goodspeed MP 1978 Maturation of the pituitary–gonadal system in the male rat. *Journal of Reproduction and Fertility* **52** 29–35. (doi:10.1530/jrf.0.0520029)
- Pruitt K & Reiter B 1985 Biochemistry of peroxidase systems: antimicrobial effects. In *The Lactoperoxidase System: Chemistry and Biological Significance*, pp143–178. Eds KM Pruitt & JO Tenovuo New York: Crc Press.
- Pusch W, Balvers M & Ivell R 1996 Molecular cloning and expression of the relaxin-like factor from the mouse testis. *Endocrinology* **137** 3009–3013. (doi:10.1210/endo-125-5-2350)
- Roberts V, Meunier H, Sawchenko PE & Vale W 1989 Differential production and regulation of inhibin subunits in rat testicular cell types. *Endocrinology* **125** 2350–2359. (doi:10.1210/endo-125-5-2350)
- Sanz E, Evanoff R, Quintana A, Evans E, Miller JA, Ko C, Amieux PS, Griswold MD & McKnight GS 2013 RiboTag analysis of actively translated mRNAs in Sertoli and Leydig cells *in vivo*. *PLoS ONE* **8** e66179. (doi:10.1371/journal.pone.0066179)
- Sharpe RM, Fraser HM & Ratnasooriya WD 1988 Assessment of the role of Leydig cell products other than testosterone in spermatogenesis and fertility in adult rats. *International Journal of Andrology* **11** 507–523. (doi:10.1111/j.1365-2605.1988.tb01024.x)
- Song WC, Qian Y, Sun X & Negishi M 1997 Cellular localization and regulation of expression of testicular estrogen sulfotransferase. *Endocrinology* **138** 5006–5012. (doi:10.1210/endo.138.11.5512)
- Stanley EL, Johnston DS, Fan J, Papadopoulos V, Chen H, Ge RS, Zirkkin BR & Jelinsky SA 2011 Stem Leydig cell differentiation: gene expression during development of the adult rat population of Leydig cells. *Biology of Reproduction* **85** 1161–1166. (doi:10.1095/biolreprod.111.091850)
- Tolosano E, Fagoonee S, Morello N, Vincini F & Fiorito V 2010 Heme scavenging and the other facets of hemopexin. *Antioxidants & Redox Signaling* **12** 305–320. (doi:10.1089/ars.2009.2787)
- Tseng CF, Lin CC, Huang HY, Liu HC & Mao SJ 2004 Antioxidant role of human haptoglobin. *Proteomics* **4** 2221–2228. (doi:10.1002/pmic.200300787)
- Vergouwen RPFA, Huiskamp R, Bas RJ, Roepers-Gajadien HL, Davids JAG & de Rooij DG 1993 Postnatal development of testicular populations in mice. *Journal of Reproduction and Fertility* **99** 479–485.
- Willems A, De Gendt K, Allemeersch J, Smith LB, Welsh M, Swinnen JV & Verhoeven G 2010 Early effects of Sertoli cell-selective androgen receptor ablation on testicular gene expression. *International Journal of Andrology* **33** 507–517.
- Yang QE, Kim D, Kaucher A, Oatley MJ & Oatley JM 2013 CXCL12–CXCR4 signaling is required for the maintenance of mouse spermatogonial stem cells. *Journal of Cell Science* **126** 1009–1020. (doi:10.1242/jcs.119826)
- Zager RA, Johnson AC & Becker K 2012 Renal cortical hemopexin accumulation in response to acute kidney injury. *American Journal of Physiology. Renal Physiology* **303** F1460–F1472. (doi:10.1152/ajprenal.00426.2012)
- Zhang FP, Rannikko A, Toppari J, Bartke A & Huhtaniemi I 1995 Developmental expression of the prolactin receptor gene in rat gonads. *Journal of Endocrinology* **147** 497–505. (doi:10.1677/joe.0.1470497)

Received 24 November 2013

First decision 17 December 2013

Revised manuscript received 3 February 2014

Accepted 6 February 2014